Croda Pharma ’s Post

One significant benefit of platelet-rich plasma (PRP) therapy is its reliance on the body's natural healing mechanisms. Unlike medication, which may mask symptoms, PRP injections target the root cause of discomfort by promoting tissue regeneration. This may help patients recover more effectively while minimizing the risk of side effects from pharmaceutical treatments. Learn more through the link below. https://lnkd.in/d-Q75Eq #PRPTherapy #PRPinjection #MedicineinMotion #StrasburgerOrthopaedics

A 20-year-old patient weighing 60 kg has to be prescribed an antiepileptic drug (available as 200 and 400 mg tablets) for generalized tonic-clonic seizures. The pharmacokinetic parameters and therapeutic plasma concentration of the selected drug are: Target steady-state plasma concentration (Cpss) – 6 mg/L Oral bioavailability (F) – 70% Volume of distribution (V) – 1.4 L/kg Clearance (CL) – 80 ml/hr/kg Plasma half life (t½) – 15 hours What should be the loading dose and the daily maintenance dose of the drug for this patient?

🔝 5 Expensive Drug 1) Lenmeldy (atidarsagene autotemcel) Cost: $4.25 million per one time treatment Indication:Metachromatic leukodystrophy (MLD) 2)Hemgenix (etranacogene dezaparvovec-drlb) Cost:$3.5 million per one-time dose Indication:Hemophilia B 3)Elevidys Cost: $3.2 million per one-time dose Indication:Duchenne Muscular Dystrophy (DMD) 4)Skysona (elivaldogene autotemcel suspension for intravenous infusion) Cost:$3 million per one-time dose Indication: Cerebral Adrenoleukodystrophy (CALD) 5)Zynteglo Cost:$2.8 million per one-time dose Indication:Beta-thalassemia #pharmacology #medicine #pharmacy

#Eohilia, as the first and only oral treatment in the US for Eosinophilic Esophagitis (#EoE), is truly a formulation and drug delivery success. The formulation contains the thixotropic agent (e.g., #Avicel RC-951), which imparts unique rheological properties to the oral formulation. These properties allow the drug suspension to become more fluid when shaken, and then return to a viscous gel state once swallowed. A viscous gel state is ideal for improving the mucoadhesion and increasing the residence time of the drug on the esophageal mucosa for EoE treatment.  #formulations, #drugdelivery

ACT I, Week II: Angiotensin II Receptor Blockers💊 Angiotensin II Receptor Blockers (ARBS) are pharmaceutical agents prescribed for managing hypertension and congestive heart failure. These medications work by selectively blocking the binding of angiotensin II to its receptors, thereby preventing blood vessel constriction and reducing blood pressure. ARBs do not interfere with the breakdown of bradykinin, minimizing the likelihood of side effects like cough. When blood vessels are narrow, the blood pressure goes up! These drugs help relax the veins & arteries, lowering the blood pressure. Side Effects: Dizziness, Fatigue, Headaches, raised Potassium Levels, and Gastrointestinal disturbances.

🌟 Key Intermediates for LY3502970 (Orforglipron) Available! 🌟 LY3502970 (orforglipron) is a once-daily oral nonpeptide GLP-1 receptor agonist. It is currently being evaluated in phase 3 clinical trials for the treatment of adults with Type 2 Diabetes. This innovative therapy has the potential to revolutionize diabetes management by offering a convenient and effective oral option for patients. 💼 We are proud to announce that we have the supply of key intermediates for LY3502970 (orforglipron). If your company is involved in the development or production of this promising treatment, let's connect! Stay tuned for more updates on this product! #Diabetes #Type2Diabetes #GLP1 #OralTherapy #Pharmaceuticals #ClinicalTrials #InnovationInHealth #IntermediatesSupply

#FDATracker: Pfizer Secures Approval for Hemophilia Treatment - BioSpace Product: Pfizer’s Hympavzi Indication: Hemophilia A and hemophilia B Friday, the FDA approved Pfizer’s Hympavzi as the first once-weekly subcutaneous prophylactic injection for hemophilia B in the U.S. Hympavzi, which was simultaneously authorized for the treatment of hemophilia A, is also the first treatment available through a pre-filled pen or syringe for either condition, according to Pfizer. Hympavzi is intended for routine prophylaxis to lower the frequency of or completely prevent bleeding episodes in patients with hemophilia. Approval of Hympavzi was supported by data from the Phase III BASIS trial, which enrolled nearly 190 patients with severe hemophilia A or moderately severe to severe hemophilia B. In this trial, treatment with Pfizer’s drug led to a 92% reduction in bleeding in patients lacking inhibitors to factor VIII or factor IX; annual bleeding rate dropped by 35%. https://lnkd.in/g-qhnb33

FDA has approved Zelsuvmi™ (berdazimer topical gel, 10.3%) for the treatment of molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older to Ligand pharmaceuticals. The FDA approved Zelsuvmi as the first novel drug for the treatment of molluscum infections. “The approval of Zelsuvmi is a breakthrough, marking the first time that clinicians can treat molluscum with an efficacious topical prescription medication that is applied by the patient, or a family member,” Zelsuvmi is a nitric oxide releasing agent. Nitric oxide has been shown to have antiviral properties.vii The mechanism of action of Zelsuvmi for the treatment of molluscum contagiosum is unknown. Zelsuvmi is expected to be available in the United States in the second half of 2024. #Zelsuvmi #ligandpharma

What are some of the material specifications for #mRNA material? What does an mRNA material #classification look like? Take a look at the short infographic below to find all the answers ⬇️ #mRNA #pharma #specifications #OnlineCourses #SymmetricTraining

📰 REGULATORY UPDATE: The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of a Type II extension of indication for amivantamab (Rybrevant) in combination with carboplatin and pemetrexed chemotherapy, according to an announcement from Janssen-cilag International Nv, a Johnson & Johnson company. The recommended extension of indication for the treatment for adults with advanced NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations after patients experience failure of prior therapy, including an EGFR tyrosine kinase inhibitor. ➡ Learn more: https://lnkd.in/gMXpn8Gv #lcsm #NSCLC